|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Novartis
gptkb:drug
|
|
gptkbp:activities
|
genetically modified T cells
|
|
gptkbp:approves
|
gptkb:large_B-cell_lymphoma
gptkb:healthcare_organization
gptkb:2017
|
|
gptkbp:associated_with
|
T-cell activation
immune response
tumor lysis syndrome
B-cell aplasia
|
|
gptkbp:clinical_trial
|
gptkb:ECOG-ACRIN_E1910
gptkb:ELIANA
Phase 2
ZUMA-1
|
|
gptkbp:collaborations
|
academic institutions
research organizations
|
|
gptkbp:competitors
|
biologic therapies
other CART therapies
|
|
gptkbp:date
|
September 2018
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
once
|
|
gptkbp:duration
|
single infusion
|
|
gptkbp:future_plans
|
combination therapies
long-term effects studies
|
|
gptkbp:healthcare
|
August 30, 2017
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kymriah
|
|
gptkbp:indication
|
B-cell malignancies
|
|
gptkbp:is_affected_by
|
monitoring required
|
|
gptkbp:is_monitored_by
|
post-infusion monitoring
|
|
gptkbp:manager
|
intravenous infusion
|
|
gptkbp:manufacturer
|
gptkb:Novartis_Pharmaceuticals_Corporation
|
|
gptkbp:marketed_as
|
gptkb:Kymriah
|
|
gptkbp:origin
|
gptkb:USA
|
|
gptkbp:population
|
pediatric and young adult patients
|
|
gptkbp:price
|
approximately $373,000
|
|
gptkbp:provides_information_on
|
ASCO guidelines
specialized cancer centers
NCCN guidelines
|
|
gptkbp:publishes
|
peer-reviewed journals
clinical trial results
|
|
gptkbp:receives_funding_from
|
gptkb:Company
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:scholarships
|
gptkb:Educational_Institution
financial assistance programs
|
|
gptkbp:setting
|
hospital or clinic
|
|
gptkbp:side_effect
|
cytokine release syndrome
neurological events
|
|
gptkbp:storage
|
frozen
|
|
gptkbp:student_enrollment
|
age 25 or younger
relapsed or refractory disease
|
|
gptkbp:targets
|
C D19
|
|
gptkbp:treatment
|
remission
improved survival rates
quality of life improvement
high response rate
durable remission
|
|
gptkbp:type
|
personalized medicine
|